Mostrar el registro sencillo del ítem
Synthesis and pharmacological screening of several aroyl and heteroaroyl selenylacetic acid derivatives as cytotoxic and antiproliferative agents
dc.creator | Sanmartín, Carmen | es_ES |
dc.creator | Plano, Daniel | es_ES |
dc.creator | Domínguez, Enrique | es_ES |
dc.creator | Font, María | es_ES |
dc.creator | Calvo, Alfonso | es_ES |
dc.creator | Prior, Celia | es_ES |
dc.creator | Encío Martínez, Ignacio | es_ES |
dc.creator | Palop, Juan Antonio | es_ES |
dc.date.accessioned | 2014-05-29T08:11:45Z | |
dc.date.available | 2014-05-29T08:11:45Z | |
dc.date.issued | 2009 | |
dc.identifier.issn | 1420-3049 | |
dc.identifier.other | 677 | |
dc.identifier.uri | https://hdl.handle.net/2454/10649 | |
dc.description.abstract | The synthesis and cytotoxic activity of a series of twenty six aroyl and heteroaroyl selenylacetic acid derivatives of general formula Ar-CO-Se-CH(2)-COOH or Heterar-CO-Se-CH(2)-COOH are reported. The synthesis was carried out by reaction of acyl chlorides with sodium hydrogen selenide, prepared in situ, and this led to the formation of sodium aroylselenides that subsequently reacted with alpha-bromoacetic acid to produce the corresponding selenylacetic acid derivatives. All of the compounds were tested against a prostate cancer cell line (PC-3) and some of the more active compounds were assessed against a panel of four human cancer cell lines (CCRF-CEM, HTB-54, HT-29, MCF-7) and one mammary gland-derived non-malignant cell line (184B5). Some of the compounds exhibited remarkable cytotoxic and antiproliferative activities against MCF-7 and PC-3 that were higher than those of the reference compounds doxorubicin and etoposide, respectively. For example, in MCF-7 when Ar = phenyl, 3, 5-dimethoxyphenyl or benzyl the TGI values were 3.69, 4.18 and 6.19 mu M. On the other hand, in PC-3 these compounds showed values of 6.8, 4.0 and 2.9 mu M. Furthermore, benzoylselenylacetic acid did not provoke apoptosis nor did it perturb the cell cycle in MCF-7. | en |
dc.format.mimetype | application/pdf | en |
dc.language.iso | eng | en |
dc.publisher | MDPI | en |
dc.relation.ispartof | Molecules, 2009, 14(9). Págs. 3313-3338 | en |
dc.rights | © 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). | en |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/ | |
dc.subject | Selenylacetic acid | en |
dc.subject | Cytotoxicity | en |
dc.subject | Apoptosis | en |
dc.subject | Prostate cancer cells | en |
dc.subject | Selenium compounds | en |
dc.subject | Organoselenium compounds | en |
dc.subject | Semiempirical methods | en |
dc.subject | Methylseleninic acid | en |
dc.subject | Diphenyl diselenide | en |
dc.subject | Growth inhibition | en |
dc.subject | Tumor cells | en |
dc.subject | In vitro | en |
dc.subject | Prevention | en |
dc.subject | Chemistry | en |
dc.title | Synthesis and pharmacological screening of several aroyl and heteroaroyl selenylacetic acid derivatives as cytotoxic and antiproliferative agents | en |
dc.type | Artículo / Artikulua | es |
dc.type | info:eu-repo/semantics/article | en |
dc.contributor.department | Ciencias de la Salud | es_ES |
dc.contributor.department | Osasun Zientziak | eu |
dc.rights.accessRights | Acceso abierto / Sarbide irekia | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | en |
dc.identifier.doi | 10.3390/molecules14093313 | |
dc.relation.publisherversion | https://dx.doi.org/10.3390/molecules14093313 | |
dc.type.version | Versión publicada / Argitaratu den bertsioa | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | en |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
La licencia del ítem se describe como © 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).